Skip to main content
Premium Trial:

Request an Annual Quote

Single Molecule Counting Tech Firm Singulex Secures $55M in Financing

NEW YORK (GenomeWeb News) – Singulex today announced it secured $55 million in debt and equity financing.

The company secured a $40 million debt facility from Oxford Finance and Silicon Valley Bank, and in June, it raised $15 million in equity financing. Singulex said it plans to use the financing to further develop its in vitro diagnostics business based on its Single Molecule Counting technology.

The Alameda, Calif.-based company raised $19 million in a financing round in January 2009.

The technology quantitatively measures "single molecules such as proteins and metabolites directly in complex biological samples without abundant protein stripping techniques," Singulex said on its website. Its flagship product is the Erenna instrument for research-use only, which detects low-abundance biomarkers and pathogens. According to Singulex, Erenna can detect single molecules down to the femtogram level.

"With the proceeds from our financing in June and this debt facility, we are now in a solid position to fund the development and regulatory approval of a fully automated diagnostic instrument and assays for the global market," President and CEO Guido Baechler said in a statement. "Expansion into the in vitro diagnostics market is a key milestone in our long-term growth strategy."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.